Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jim Cassidy

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Clinical Colorectal Cancer|August 16, 2005
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II studyChris J Twelves, Charles A Butts, Jim Cassidy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2008
Potential regional differences for the tolerability profiles of fluoropyrimidinesDaniel G Haller, Jim Cassidy, Stephen J Clarke, et al.
The New England Journal of Medicine|July 1, 2005
Capecitabine as adjuvant treatment for stage III colon cancerChris Twelves, Alfred Wong, Marek P Nowacki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2026
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority TrialTimothy Iveson, Mark P Saunders, Caroline Kelly, et al.
JAMA Surgery|June 12, 2024
Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy: Post Hoc Analysis of the SCOT Randomized Clinical TrialMikail Gögenur, Andreas Weinberger Rosen, Timothy Iveson, et al.
The Lancet. Oncology|April 4, 2018
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trialTimothy J Iveson, Rachel S Kerr, Mark P Saunders, et al.
British Journal of Cancer|November 14, 2018
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancerJosé Robles-Zurita, Kathleen A Boyd, Andrew H Briggs, et al.
Health Technology Assessment (Winchester, England)|December 20, 2019
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCTTimothy Iveson, Kathleen A Boyd, Rachel S Kerr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 28, 2015
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset, Josef Thaler, Richard Greil, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Clinical Colorectal Cancer|August 16, 2005
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II studyChris J Twelves, Charles A Butts, Jim Cassidy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2008
Potential regional differences for the tolerability profiles of fluoropyrimidinesDaniel G Haller, Jim Cassidy, Stephen J Clarke, et al.
The New England Journal of Medicine|July 1, 2005
Capecitabine as adjuvant treatment for stage III colon cancerChris Twelves, Alfred Wong, Marek P Nowacki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2026
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority TrialTimothy Iveson, Mark P Saunders, Caroline Kelly, et al.
JAMA Surgery|June 12, 2024
Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy: Post Hoc Analysis of the SCOT Randomized Clinical TrialMikail Gögenur, Andreas Weinberger Rosen, Timothy Iveson, et al.
The Lancet. Oncology|April 4, 2018
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trialTimothy J Iveson, Rachel S Kerr, Mark P Saunders, et al.
British Journal of Cancer|November 14, 2018
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancerJosé Robles-Zurita, Kathleen A Boyd, Andrew H Briggs, et al.
Health Technology Assessment (Winchester, England)|December 20, 2019
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCTTimothy Iveson, Kathleen A Boyd, Rachel S Kerr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 28, 2015
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset, Josef Thaler, Richard Greil, et al.
Pageof 5